Watch ZVSA. Know when insiders buy.
One email the day a filing lands. Free.
ZVSA
ZyVersa Therapeutics, Inc.
0.08
+0.00 +0.00%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $648KP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$24.5MNET CASH —52W 0.08 – 0.27SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2026 · Mar 31 | — | — | — | −$1.3M | −$1.8M | — | -0.22 | −$799K | — | — | May 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$552K | −$679K | — | 0.45 | −$414K | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$20.8M | −$19.8M | — | -2.56 | −$1.4M | — | — | Nov 19 |
| Q2 2025 · Jun 30 | — | — | — | −$2M | −$2.2M | — | -0.46 | −$1.5M | — | — | Nov 19 |
| Q1 2025 · Mar 31 | — | — | — | −$2.1M | −$2.3M | — | -0.73 | −$1.8M | — | — | May 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.3M | −$1.4M | — | 1.31 | −$1.2M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$2.3M | −$2.4M | — | -2.43 | −$614K | — | — | Nov 19 |
| Q2 2024 · Jun 30 | — | — | — | −$2.8M | −$2.8M | — | -3.31 | −$1.9M | — | — | Nov 19 |
| Q1 2024 · Mar 31 | — | — | — | −$2.8M | −$2.8M | — | -4.53 | −$3.8M | — | — | Nov 19 |
| Q4 2023 · Dec 31derived | — | — | — | −$13.9M | −$13.3M | — | 501.76 | −$2.8M | — | — | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$2.9M | −$2.9M | — | -30.18 | −$936K | — | — | Nov 14 |
| Q2 2023 · Jun 30 | — | — | — | −$86.3M | −$78.5M | — | -1694.12 | −$408K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$25.5M | −$25M | — | -4.18 | −$5.1M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$9.1M | −$9.4M | — | -8.48 | −$7.5M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$107.8M | −$98.3M | — | -1089.70 | −$8.7M | — | — | — | — |
| FY2022 · to Dec 12 | — | — | −$13M | −$14M | — | -0.99 | −$1.5M | — | — | — | — |
Every number comes from ZyVersa Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.